The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Safety and preliminary efficacy of elotuzumab and belantamab mafodotin in patients with R/R myeloma
Natalia Neparidze, MD, Yale School of Medicine, New Haven, CT, discusses the findings of a Phase Ib/II study (NCT05002816) investigating the safety and tolerability of combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory (R/R) multiple myeloma (MM). This combination had a manageable safety profile with no dose-limiting toxicities (DLTs) reported and demonstrated encouraging preliminary efficacy in a heavily pretreated cohort of patients. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Janssen, GSK.
